Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
06 Février 2024 - 7:30AM
UK Regulatory
Nicox announces presentations at the upcoming Association for
Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
Press Release |
Nicox announces presentations at the upcoming Association for
Research in Vision and Ophthalmology (ARVO) Annual Meeting
2024 |
February 6, 2024 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Growth Paris: FR0013018124,
ALCOX), an international ophthalmology company, today announced
presentations on NCX 470 and NCX 1728 at the upcoming Association
for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2024, a key ophthalmology conference which will be held from May 5
to May 9, 2024 in Seattle, WA, United States.
Abstract/Presentation Title: Tolerability and
intraocular pressure (IOP)-lowering efficacy following 5-day
repeated dosing with NCX 470 0.1% ophthalmic solution,
Lumigan® and Rhopressa®: a comparative
head-to-head study in rabbits and dogs
Type: Poster Session
Session Title: Tools and advancements in glaucoma
diagnosis, monitoring, medications, and lasers
Date: May 6, 2024 from 8:30 am to 10:15 am (U.S.
local time)
Presenter: Francesco Impagnatiello, PhD, Nicox
Research Institute
NCX 470, a novel NO-donating bimatoprost eye drop, is currently in
Phase 3 clinical development for the lowering of intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension. Results of Mont Blanc, the first of the two Phase 3
clinical trials, have been announced in October 2022. The second
Phase 3 clinical trial, Denali, is currently ongoing, and the
results are expected in 2025, based on current recruitment
rates.
Abstract/Presentation Title: NCX 1728, a novel
nitric oxide (NO)-donating avanafil: Formulation development and in
vivo testing in a rabbit model of ischemia/reperfusion injury of
the optic nerve head and retina
Type: Poster Session
Session Title: Neuroprotection, blood flow,
ischemia-reperfusion and aqueous humor dynamics
Date: May 5, 2024 from 3:15 pm to 5:00 pm (U.S.
local time)
Presenter: Corinna Galli, PhD, Nicox Research
Institute
NCX 1728 is an NO-donating phosphodiesterase-5 (PDE5) inhibitor,
the lead compound in a new class of NO-donating molecules based
entirely on NO-mediated activity. NCX 1728 is currently under
preclinical evaluation for development in retinal conditions.
Nicox Corporate Status Update
The Company estimates it is financed until June 2024, based
exclusively on the development of NCX 470. The Company is pursuing
licensing and other business development discussions, exploring
multiple strategic options and is also discussing with its
creditors to restructure its debt. |
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost eye drop, for lowering
intraocular pressure in patients with open-angle glaucoma or ocular
hypertension. Nicox generates revenue from VYZULTA® in
glaucoma, licensed exclusively worldwide to Bausch + Lomb, and
ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and
Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on
Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC
Healthcare index.
For more information www.nicox.com. |
Analyst coverage |
Bryan, Garnier & Co
Eric
Yoo Paris,
France
H.C. Wainwright &
Co Yi
Chen New York,
U.S. |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com |
|
Forward-Looking Statements |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.
Risks factors which are likely to have a material effect on Nicox’s
business are presented in section 2.7 of the “Rapport Annuel
2022” and in section 4 of the “Rapport semestriel
financier et d’activité 2023” which are available on Nicox’s
website (www.nicox.com). |
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99 |
|
- EN_ARVO 2024_ABSTRACTS_ 20240206_F
Nicox (LSE:0RCQ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Nicox (LSE:0RCQ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024